Home » Stocks » Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. (SLRX)

Stock Price: $1.18 USD 0.04 (3.07%)
Updated Aug 10, 2020 10:57 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 17.20M
Revenue (ttm) 3.94M
Net Income (ttm) -7.98M
Shares Out 14.64M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $1.18
Previous Close $1.14
Change ($) 0.04
Change (%) 3.07%
Day's Open 1.16
Day's Range 1.16 - 1.19
Day's Volume 63,703
52-Week Range 0.56 - 13.50

More Stats

Market Cap 17.20M
Enterprise Value 7.81M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 14.64M
Float 10.96M
EPS (basic) -3.39
EPS (diluted) -1.48
FCF / Share -1.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 984,161
Short Ratio 2.06
Short % of Float 6.56%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.36
PB Ratio 0.97
Revenue 3.94M
Operating Income -9.59M
Net Income -7.98M
Free Cash Flow -12.63M
Net Cash 9.39M
Net Cash / Share 0.64
Gross Margin -14.05%
Operating Margin -243.21%
Profit Margin -248.50%
FCF Margin -320.36%
ROA -35.42%
ROE -76.53%
ROIC 696.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.40*
(274.47% upside)
Low
3.80
Current: $1.18
High
5.00
Target: 4.40
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue3.471.951.851.01-
Revenue Growth77.57%5.37%83.24%--
Gross Profit3.471.951.850.35-
Operating Income-8.27-1.68-1.75-39.89-29.21
Net Income-6.94-1.67-1.75-39.49-29.14
Shares Outstanding3.271.541.150.650.56
Earnings Per Share-2.12-1.16-1.60-60.75-52.00
Operating Cash Flow-11.584.18-1.46-32.05-20.75
Capital Expenditures----0.55-0.27
Free Cash Flow-11.584.18-1.46-32.61-21.01
Cash & Equivalents3.746.130.5261.2091.47
Total Debt0.50----
Net Cash / Debt3.246.130.5261.2091.47
Assets13.896.610.6963.2195.07
Liabilities3.317.881.723.902.88
Book Value10.58-1.27-2.9059.3292.19
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Salarius Pharmaceuticals, Inc.
Country United States
Employees 7
CEO David J. Arthur

Stock Information

Ticker Symbol SLRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SLRX

Description

Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.